Latest News

Genmab Enters Commercial License Agreement with Gilead for DuoBody® Technology

10 Aug 2016

New commercial DuoBody technology platform collaboration with Gilead. Genmab granted Gilead an exclusive license to create a bispecific antibody with the DuoBody technology and an option to obtain a second exclusive license. Please read the full article here.